Psych Capital Plc

Psych Capital identifies, funds and aims to support the building of British and European companies across three core pillars: therapeutic treatments, drug development, and data/AI.

Our mission is to support a new wave of innovators who are well positioned to challenge the status-quo and revolutionise how society deals with mental health conditions.

In this rapidly emerging market it can be difficult for industry outsiders to conduct the due diligence needed to identify meaningful innovations and commercial opportunities.

Through a network of analysts with deep industry knowledge and capital markets expertise, Psych Capital is focussed on developing a rigorously selected portfolio of industry leading companies at the intersection of psychedelic medicine and technology.